{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 445909355
| IUPAC_name = (1''R'',3''R'',7''E'',17β)-17-[(1''R'',2''E'',4''S'')-5-hydroxy-1,4,5-trimethylhex-2-en-1-yl]-9,10-secoestra-5,7-diene-1,3-diol
| image = Paricalcitol.svg
| width = 200px
| image2 = Paricalcitol3Dan.gif
| width2 = 200px
<!--Clinical data-->
| tradename =  Zemplar
| Drugs.com = {{drugs.com|monograph|paricalcitol}}
| MedlinePlus = a682335
| pregnancy_AU = C
| pregnancy_US = C
| pregnancy_category = 
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral, Intravenous
<!--Pharmacokinetic data-->
| bioavailability = 72%<ref name = MSR/>
| protein_bound = 99.8%<ref name = MSR/>
| metabolism = [[Hepatic]]<ref name = MSR/>
| elimination_half-life = 14-20 hours<ref name = MSR/>
| excretion = Faeces (74%), urine (16%)<ref name = MSR/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 131918-61-1
| ATC_prefix = H05
| ATC_suffix = BX02
| ATC_supplemental =  
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7931
| PubChem = 5281104
| IUPHAR_ligand = 2791
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00910
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4444552
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6702D36OG5
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00930
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1200622
<!--Chemical data-->
| chemical_formula =
| C=27 | H=44 | O=3
| molecular_weight = 416.636 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BPKAHTKRCLCHEA-UBFJEZKGSA-N
| synonyms = <small>(1''R'',3''S'')-5-[2-[(1''R'',3a''R'',7a''S'')-1-<nowiki>[</nowiki>(2''R'',5''S'')-6-hydroxy-5,6-dimethyl-3''E''-hepten-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1''H''-inden-4-ylidene]ethylidene]-cyclohexane-1,3-diol</small>
}}

'''Paricalcitol''' (chemically it is '''19-nor-1,25-(OH)<sub>2</sub>-vitamin D<sub>2</sub>'''. Marketed by [[Abbott Laboratories]] under the trade name '''Zemplar''') is a [[pharmaceutical drug|drug]] used for the prevention and treatment of [[secondary hyperparathyroidism]] (excessive secretion of [[parathyroid hormone]]) associated with [[chronic renal failure]]. It is an [[analog (chemistry)|analog]] of 1,25-dihydroxyergocalciferol, the active form of [[Vitamin D2|vitamin D<sub>2</sub>]] (ergocalciferol).

==Medical uses==
Its primary use in medicine is in the treatment of secondary hyperparathyroidism associated with chronic kidney disease.<ref name="AMH">{{cite book | editor = Rossi, S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref> In three placebo-controlled studies, chronic renal failure patients treated with paricalcitol achieved a mean parathyroid hormone (PTH) reduction of 30% in six weeks. Additionally there was no difference in incidence of hypercalcemia or hyperphosphatemia when compared to placebo.<ref>[http://www.medilexicon.com/drugs/zemplar.php "Zemplar: Drug Information"]</ref> A double-blind randomised study with 263 dialysis patients showed a significant advantage over [[calcitriol]] (also known as activated vitamin D<sub>3</sub>; a similar molecule to 1,25-dihydroxyergocalciferol, adding a methyl group on C<sub>24</sub> and lacking a double-bond in the C<sub>22</sub> position). After 18 weeks, all patients in the paricalcitol group had reached the target parathormone level of 100 to 300 pg/ml, versus none in the calcitriol group.<ref>Schubert-Zsilavecz, M, Wurglics, M, ''Neue Arzneimittel 2005/2006'' (in German).</ref> Combination therapy with paricalcitol and [[trandolapril]] has been found to reduce [[fibrosis]] in [[obstructive uropathy]].<ref>{{cite journal|doi=10.1038/ki.2009.346|pmid=19759524|year=2009|last1=Tan|first1=X|last2=He|first2=W|last3=Liu|first3=Y|title=Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy|volume=76|issue=12|pages=1248–57|journal=Kidney International}}</ref> Forty-eight-week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures of diastolic dysfunction in 227 patients with chronic kidney disease.<ref>{{cite journal|doi=10.1001/jama.2012.120|pmid=22337679|year=2012|last1=Thadhani|first1=R|last2=Appelbaum|first2=E|last3=Pritchett|first3=Y|title=Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease - The PRIMO Randomized Controlled Trial|volume=307|issue=7|pages=674–684|journal=JAMA|last4=Chang|first4=Y|last5=Wenger|first5=J|last6=Tamez|first6=H|last7=Bhan|first7=I|last8=Agarwal|first8=R|last9=Zoccali|first9=C|last10=Wanner|first10=Christoph|last11=Lloyd-Jones|first11=Donald|last12=Cannata|first12=Jorge|last13=Thompson|first13=B. Taylor|last14=Andress|first14=Dennis|last15=Zhang|first15=Wuyan|last16=Packham|first16=David|last17=Singh|first17=Bhupinder|last18=Zehnder|first18=Daniel|last19=Shah|first19=Amil|last20=Pachika|first20=Ajay|last21=Manning|first21=Warren J.|last22=Solomon|first22=Scott D.|display-authors=8}}</ref>

==Adverse effects==
'''Adverse effects by frequency:'''<ref name = MSR>{{cite web|title=Zemplar (paricalcitol) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=26 January 2014|url=http://reference.medscape.com/drug/zemplar-paricalcitol-342830#showall}}</ref><ref name="AMH"/><ref name = DM>{{cite web|title=PARICALCITOL capsule, liquid filled [Teva Pharmaceuticals USA Inc]|work=DailyMed|publisher=Teva Pharmaceuticals USA Inc|accessdate=26 January 2014|url=http://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=c233cba2-d645-426c-9e4d-ef616edc7903&type=pdf&name=c233cba2-d645-426c-9e4d-ef616edc7903|format=PDF|date=September 2013}}</ref><ref name = EMC>{{cite web|title=Zemplar Soft Capsules 1 mcg - Summary of Product Characteristics|publisher=AbbVie Limited|work=electronic Medicines Compendium|date=15 April 2013|accessdate=26 January 2014|url=http://www.medicines.org.uk/emc/medicine/20464/SPC/Zemplar+Soft+Capsules+1+mcg/}}</ref><br />
'''Very common (>10% frequency):'''
* Nausea

'''Common (1-10% frequency):'''
{{colbegin|4}}
* Diarrhoea<sup>†</sup>
* [[Oedema]]
* Allergic reaction
* [[Arthritis]]
* Dizziness<sup>†</sup>
* Stomach discomfort<sup>‡</sup>
* [[Gastroesophageal reflux disease]]<sup>†</sup>
* [[Acne]]<sup>†</sup>
* [[Hypercalcaemia]]<sup>†</sup>
* [[Hypocalcaemia]]<sup>†</sup>
* [[Hyperphosphataemia]]
* Decreased appetite<sup>†</sup>
* Headache
* Breast tenderness<sup>†</sup>
* Taste changes
* [[Hypoparathyroidism]]
* Vertigo
* Rash<sup>‡</sup>
{{colend}}

'''Uncommon (0.1-1% frequency):'''
{{colbegin|4}}
* Abnormal hepatic enzymes<sup>‡</sup>
* Constipation<sup>‡</sup>
* Dry mouth<sup>‡</sup>
* [[Pruritus|Itchiness]]<sup>‡</sup>
* [[Urticaria|Hives]]
* Hypersensitivity<sup>‡</sup>
* Muscle spasms<sup>‡</sup>
* Bleeding time prolonged
* Aspartate aminotransferase increased
* Laboratory test abnormal
* Weight loss
* Elevated blood creatinine
* Cardiac arrest
* Arrhythmia
* Atrial flutter
* [[Anaemia]]
* [[Leucopenia]]
* Lymphadenopathy
* Coma
* [[Cerebrovascular accident|Stroke]]
* [[Transient ischemic attack]]
* [[Vasovagal syncope|Fainting]]
* [[Myoclonus]]
* [[Hypoaesthesia]]
* [[Paraesthesia]]
* [[Glaucoma]]
* [[Conjunctivitis]]
* Ear disorder
* Pulmonary oedema
* Asthma
* [[Dyspnoea|Shortness of breath]]
* [[Epistaxis|Nose bleed]]
* Cough
* Rectal haemhorrhage
* [[Colitis]]
* [[Gastritis]]
* [[Dyspepsia|Indigestion]]
* [[Dysphagia|Difficulty swallowing]]
* Gastrointestinal disorder
* Gastrointestinal haemorrhage
* Bullous dermatitis
* [[Alopecia|Hair loss]]
* [[Hirsutism]]
* [[Hyperhidrosis]]
* [[Arthralgia|Joint pain]]
* Joint stiffness
* Back pain
* Muscle twitching
* [[Myalgia|Muscle aches]]
* [[Hyperparathyroidism]]
* [[Hyperkalaemia]]
* [[Hypocalcemia]]
* [[Breast cancer]]
* [[Sepsis]]
* [[Pneumonia]]
* Infection
* [[Pharyngitis]]
* Vaginal infection
* Influenza
* [[Hypertension|High blood pressure]]
* [[Hypotension]]
* Gait disturbance
* Injection site pain
* [[Pyrexia|Fever]]
* Chest pain
* Condition aggravated
* [[Asthenia|Muscle weakness]]
* [[Malaise]]
* Thirst
* Breast pain
* [[Erectile dysfunction|Impotence]]
* Confusional state
* Delirium
* Depersonalization
* Agitation
* Insomnia
* Nervousness
{{colend}}

<sup>‡</sup> These are adverse effects only seen in patients with grade 3 or 4 chronic kidney disease. 
<sup>†</sup> These are adverse effects only seen in patients with grade 5 chronic kidney disease.

===Contraindications===
Contraindications include:<ref name = EMC/>
* [[Hypervitaminosis D|Vitamin D intoxication]]
* [[Hypercalcaemia]]
* Hypersensitivity to paricalcitol or any of its excipients

whereas cautions include:<ref name = MSR/>
* Impaired liver function
* It is also advised that physicians regularly monitor their patients' [[calcium]] and [[phosphorus]] levels.

===Interactions===
Drugs that may interact with paricalcitol include:<ref name = MSR/><ref name = EMC/> 
{{colbegin|2}}
* [[Ketoconazole]], as it may interfere with paricalcitol's metabolism in the liver.
* [[Digitoxin]], hypercalcaemia due to any cause can exacerbate the toxicity of digitoxin.
* [[Thiazide]] diuretics or calcium supplements as [[hypercalcaemia]] may be induced by this combination
* [[Magnesium]]-containing products such as [[antacids]] may increase the risk of [[hypermagnesemia]].
* [[Aluminium]]-containing products such as antacids may increase the risk of [[aluminium toxicity]].
* Drugs that interfere with the absorption of fat-soluble vitamins, such as [[cholestyramine]] may interfere with the absorption of paricalcitol. 
{{colend}}

===Overdose===
Electrolyte abnormalities (e.g. [[hypercalcaemia]] and [[hyperphosphataemia]]) are common overdose symptoms.<ref name = EMC/> Treatment is mostly supportive, with particular attention being paid to correcting electrolyte anomalies and reducing intake of calcium in both the form of supplementation and diet.<ref name = EMC/> As it is so heavily bound to plasma proteins [[haemodialysis]] is unlikely to be helpful in cases of overdose.<ref name = EMC/>

Early symptoms of overdose can include:<ref name = EMC/>
{{colbegin|4}}
* Weakness
* Headache
* Somnolence
* Nausea
* Vomiting
* Dry mouth
* Constipation
* Muscle pain
* Bone pain
* Metallic taste in the mouth.
{{colend}}
It is worth noting, however, that may of these symptoms are also indicative of kidney failure and hence may be masked by the patient's condition.<ref name = EMC/>

Late symptoms of overdose include:
{{colbegin|4}}
* [[Anorexia (symptom)|Loss of appetite]]
* Weight loss
* [[Conjunctivitis]] (calcific)
* [[Pancreatitis]]
* Photophobia
* Rhinorrhoea
* Pruritus
* Hyperthermia
* Decreased libido
* Elevated BUN
* Hypercholesterolaemia
* Elevated AST and ALT
* Ectopic calcification
* Hypertension
* Cardiac arrhythmias
* Somnolence
* Death
* Psychosis (rare)
{{colend}}

==Mechanism of action==
[[File:Paricalcitol structure.svg|thumb|left|3D structure of paricalcitol]]{{clear left}}
Like 1,25-dihydroxyergocalciferol, paricalcitol acts as an [[agonist]] at the [[vitamin D receptor]] and thereby lowers [[parathyroid hormone]] levels in the blood.<ref name = MSR/>

==Pharmacokinetics==
The plasma concentration of paricalcitol decreases rapidly and log-linearly within two hours after initial intravenous administration. Therefore, it is not expected to accumulate with multiple dosing, since paricalcitol is usually given no more frequently than every other day (3 times per week).<ref name="Rxlist">Rxlist: [http://www.rxlist.com/zemplar-drug.htm Zemplar]</ref><ref name="paricalcitol PI">{{cite book|title=Zemplar (paricalcitol) [prescribing information].|date=October 1, 2015|publisher=AbbVie Inc.|location=North Chicago, IL|accessdate=December 12, 2016}}</ref>

==References==
{{Reflist|2}}

{{Vitamins}}
{{Calcium homeostasis}}
{{Vitamin D receptor modulators}}

[[Category:Secosteroids]]
[[Category:Vitamin D]]